Regenxbio Inc
Change company Symbol lookup
Select an option...
RGNX Regenxbio Inc
SGBXV Safe & Green Holdings Corp
GOOG Alphabet Inc
WHLR Wheeler Real Estate Investment Trust Inc
FRHLF Freehold Royalties Ltd
CTNT Cheetah Net Supply Chain Service Inc
LASE Laser Photonics Corp
GFR M3-Brigade Acquisition III Corp
PCT Purecycle Technologies Inc
UPST Upstart Holdings Inc
Go

Health Care : Biotechnology | Small Cap Value

REGENXBIO Inc. is a clinical-stage biotechnology company, which is focused on providing curative potential of gene therapy. Its investigational gene therapies are designed to deliver functional genes to address genetic defects in cells. The Company’s investigational AAV Therapeutics include RGX-314, RGX-202, RGX-121, RGX-111 and RGX-181 and RGX-381. RGX-314 is meant for the treatment of large patient populations impacted by wet age-related macular degeneration (wet AMD), diabetic retinopathy and other chronic retinal diseases. RGX-202 is developed to treat Duchenne muscular dystrophy, one of the common fatal genetic disorders affecting children. RGX-121, RGX-111 and RGX-181 are developed to treat Mucopolysaccharidosis type II, Mucopolysaccharidosis type I, and late infantile neuronal ceroid lipofuscinosis type II (CLN2 disease), all of which are progressive, neurodegenerative lysosomal storage disorders. RGX-381 is developed to treat the ocular manifestations of CLN2 disease.

Closing Price: $17.11

Day's Change: -0.51 (-2.89%)

Bid: --

Ask: --

B/A Size: --

Day's High: 17.62

Day's Low: 17.10

Volume (Average) Volume: 363,971 10-day average volume: 377,983: 363,971

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.